Eribulin - Uses, Dosage, Side Effects and More

Introduction: What is Eribulin?

Eribulin is a chemotherapy medication primarily used to treat certain types of breast cancer. It is a synthetic derivative of a natural compound found in the sea sponge Halichondria okadai. Approved by the FDA, Eribulin is often prescribed for patients with metastatic breast cancer who have previously undergone multiple treatments. Its unique mechanism of action and effectiveness in specific cancer types make it a valuable option in oncology.

Uses of Eribulin

Eribulin is primarily indicated for:

• Metastātisks krūts vēzis: Metastatic or unresectable breast cancer in patients who have previously received at least two chemotherapy regimens, including an anthracycline and a taxane.
• Lokāli progresējošs krūts vēzis: It can be used in patients who are not candidates for surgery or radiation.
• Soft Tissue Sarcoma (Liposarcoma): Approved for patients with unresectable or metastatic liposarcoma who have previously received an anthracycline-containing regimen.

Kā tas darbojas

Eribulin works by disrupting the normal function of microtubules, which are essential components of the cell's structure and play a critical role in cell division. In simpler terms, it prevents cancer cells from dividing and growing, ultimately leading to their death. By halting the process of cell division, Eribulin effectively slows down or stops the progression of cancer.

Devas un ievadīšana

Eribulin is administered via injection, typically into a vein (intravenous). The standard dosage for adults is:

• Sākotnējā deva: 1.4 mg/m? of body surface area, given on days 1 and 8 of a 21-day cycle.
• Devas bērniem: Safety and efficacy in children have not been established, so it is not typically recommended for pediatric use.

The healthcare provider will determine the exact dosage based on individual patient factors, including overall health and response to treatment.

Side Effects of Eribulin

Biežas blakusparādības var būt:

• Nogurums
• Slikta dūša un vemšana
• Matu izkrišana
• Aizcietējums
• Samazināta apetīte

Nopietnas blakusparādības var ietvert:

• Febrile neutropenia (low white blood cell count)
• Perifēra neiropātija (nejutīgums vai tirpšana rokās un kājās)
• Aknu problēmas
• QT interval prolongation and cardiac rhythm abnormalities

Pacientiem nekavējoties jāziņo savam veselības aprūpes speciālistam par visiem smagiem vai neparastiem simptomiem.

Narkotiku mijiedarbība

Eribulin may interact with several medications, including:

• Strong P-glycoprotein (P-gp) inhibitors may increase Eribulin exposure and should be used with caution.
• Other Chemotherapy Agents: Combining Eribulin with certain other chemotherapy drugs may increase the risk of side effects.

Vienmēr informējiet savu veselības aprūpes sniedzēju par visām zālēm un uztura bagātinātājiem, ko lietojat.

Benefits of Eribulin

The clinical advantages of Eribulin include:

• Efektivitāte: It has shown effectiveness in patients with heavily pretreated metastatic breast cancer.
• Unikāls mehānisms: Its distinct action on microtubules offers an alternative for patients who have not responded to other treatments.
• Dzīves kvalitāte: Some studies suggest Eribulin may help maintain quality of life compared to other late-line chemotherapies.

Contraindications of Eribulin

Eribulin should be avoided in certain populations, including:

• Sieviete stāvoklī: Tas var kaitēt auglim.
• Patients with Severe Hepatic Impairment: Liver function can affect drug metabolism and increase toxicity.
• Alerģiskas reakcijas: Individuals with known hypersensitivity to Eribulin or its components should not use it.

Piesardzības pasākumi un brīdinājumi

Before starting Eribulin, patients should undergo:

• Aknu funkcionālie testi: Lai novērtētu aknu veselību.
• Complete Blood Count (CBC): To monitor blood cell levels, especially white blood cells.
• Electrolyte levels and ECG monitoring may be required in patients at risk for QT prolongation.

Patients should also be aware of the potential for severe side effects and discuss any preexisting conditions with their healthcare provider.

Biežāk uzdotie jautājumi

• What is Eribulin used for? Eribulin is used to treat metastatic breast cancer in patients who have received prior chemotherapy.
• How is Eribulin administered? It is given as an injection into a vein, typically on days 1 and 8 of a 21-day cycle.
• Kādas ir biežas blakusparādības? Common side effects include fatigue, nausea, hair loss, and constipation.
• Can Eribulin be used in children? Its safety and effectiveness in children have not been established, so it is not typically recommended.
• Kas man jādara, ja esmu izlaidusi devu? Sazinieties ar savu veselības aprūpes sniedzēju, lai saņemtu norādījumus par to, kā rīkoties, ja esat izlaidis devu.
• Is Eribulin safe during pregnancy? No, Eribulin is contraindicated in pregnant women due to potential harm to the fetus.
• How does Eribulin work? It disrupts microtubule function, preventing cancer cells from dividing and growing.
• What should I tell my doctor before starting Eribulin? Inform your doctor about all medications, supplements, and any preexisting health conditions.
• Can I drink alcohol while taking Eribulin? Alcohol should be consumed with caution, especially in patients with liver dysfunction.
• How often will I need to see my doctor while on Eribulin? Regular follow-up appointments will be necessary to monitor your response to treatment and manage side effects.

Zīmolu nosaukumi

Eribulin is marketed under the brand name Halaven.

Secinājumi

Eribulin is a significant option in the treatment of metastatic breast cancer, particularly for patients who have exhausted other therapies. Its unique mechanism of action, along with its specific indications and potential side effects, makes it essential for patients and healthcare providers to have thorough discussions about its use. Always consult with a healthcare professional for personalized medical advice.